Expression of surface markers on peripheral CD4＋CD25^high T cells in patients with atopic asthma： role of inhaled corticosteroid

Background CD4^＋CD25^＋ regulatory T cells （Tregs） mediate immune suppression through cell-cell contact with surface molecules, particularly cytotoxic T lymphocyte-associated antigen 4 （CTLA-4）, glucocorticoid-induced tumor necrosis factor receptor family-related protein （GITR）, and transforming growth factor β （TGF-β）, but little is known about the exact role of Tregs in the pathogenesis of asthma. This study sought to characterize the expression of surface markers on peripheral blood mononuclear cells-derived Tregs in patients with atopic asthma and healthy subjects, and to investigate the effect of inhaled corticosteroid on them.
Methods The expression of surface molecules on CD4^＋CD25^high Tregs was detected by flow cytometry. The effect of inhaled corticosteroid on expression of the surface molecules on Tregs was determined in vivo and in vitro. Total serum immunoglobulin E （IgE） and high-sensitivity C-reactive protein were measured by enzyme linked immunosorbent assay and latex enhanced immunoturbidimetric assay, respectively. Results Equivalent numbers of peripheral Tregs were found in patients with atopic asthma （stable and acute） and healthy subjects. Tregs preferentially expressed CTLA-4, GITR, toll-like receptor 4 （TLR4）, latency-associated peptide （LAP/FGF-β1）, and forkhead box P3 （FOXP3）. Patients with acute asthma had decreased numbers of CD4^＋CD25^highLAP^＋ T cells compared to healthy subjects and stable asthmatics. Inhaled corticosteroid enhanced the percentage of Tregs expressing LAP in vivo and in vitro dose-dependently. Furthermore, the percentages of Tregs expressing LAP were negatively correlated with total serum IgE levels and severity of asthma, but positively correlated with forced expiratory volume in one second percentage of the predicted value in patients with asthma.
Conclusions The results suggest that membrane-bound TGF-β1 is a potential candidate for predicting the severity of asthma, and may contribute to the sustained remission     

Analysis of CD4^＋CD25^＋ Regulatory T Cells and Foxp3 mRNA in the Peripheral Blood of Patients with Asthma

The changes of CD4 CD25 regulatory T cells (CD4 CD25 Treg) and Foxp3 mRNA in peripheral blood mononuclear cells (PBMCs) from patients with asthma were investigated in order to elucidate the possible roles of CD4 CD25 Treg in the development of asthma. The peripheral blood samples were collected from 29 healthy controls (normal control group) and 78 patients with asthma which included 30 patients in exacerbation group, 25 patients in persistent group, and 23 patients in remission group. By using flow cytometry and RT-PCR, the CD4 CD25 Treg ratio and Foxp3 mRNA in PBMCs were detected. The CD4 CD25 Treg ratio and Foxp3 mRNA in PBMCs of exac-erbation and persistent groups were lower than that of remission and normal control groups (P<0.05). Although the CD4 CD25 Treg ratio and Foxp3 mRNA of remission group were also lower than that of normal control group, there was no significant difference between them (P>0.05). As compared with persistent group, exacerbation group had lower CD4 CD25 Treg ratio and Foxp3 mRNA (P<0.05). It was indicated that the decrease of CD4 CD25 Treg ratio and its function in PBMCs may be responsible for pathogenesis of asthma.     

Changes of Regulatory T Cells in Graves＇ Disease

The immune mechanism of Graves＇ diseases （GD） and the roles of regulator T cells were investigated. In 32 patients with GD （GD group） and 20 healthy volunteers （control group）, flow cytometry was used to detect the proportion of CD4^＋CD25^＋ cells, MACS to isolate CD4^＋ CD25^＋ cells, RT-PCR to assay the expression of FOXP3, and ELISA to test the leyel of IL-10, respectively. It was found that there was no significant change in the proportion of CD4^＋CD25^＋ T cells between GD group and control group （P〉0.05）, while secretion of IL-10 and expression of FOXP3 in GD group were lower than control group （P〈0.01 and P〈0.05, respectively）. In conclusion, though the proportion of regulatory T cells of peripheral blood lymphocytes in the patients with GD, the functions of them were significantly weakened, which might be a pathogenic factor in GD.     

Changes of CD4^＋CD25^＋ Regulatory T Cells in Patients with Acute Coronary Syndrome and the Effects of Atorvastatin

The function of CD4＋CD25＋ regulatory T lymphocytes （Treg） in patients with acute coronary syndrome （ACS） and the effects of atorvastatin were investigated. Forty-eight patients with ACS were randomly divided into two groups： group C receiving conventional therapy （n=24）, and group C＋A receiving conventional therapy＋atorvastatin （10 mg/day, n=24）. T lymphocytes from ACS patients （before and 2 weeks after the treatment） or 18 healthy subjects were separated and the flow cytometry was used to measure the percentage of Treg. The inhibitory ability of Treg on effector T cells was determined by mixed lymphocyte reaction （MLR）. ELISA was used to measure the serum levels of cytokines （IL-10, TGF-β1 and IFN-γ） before and after treatment. The results showed that as compared with normal control group, Treg percentage was decreased significantly （P〈0.01）, the inhibitory ability of Treg on the T lymphocytes proliferation was reduced （P〈0.01）, IFN-γ levels were increased and IL-10 and TGF-β1 levels were lowered in ACS patients. After treatment with atorvastatin, Treg percentage and the inhibitory ability of Treg on T lymphocytes proliferation were significantly increased in ACS patients. Serum IFN-γ was decreased significantly, while IL-10 and TGF-β1 were elevated significantly as compared with the non-atorvastatin group. The number of Treg was positively correlated with serum TGF-β1, but negatively with serum IFN-γ and CRP. It was concluded that ACS was associated with decreased number and defected function of Treg, which may play an important role in initiating immune-inflammatory response in ACS. The inhibitory effects of atorvastatin on inflammation in ACS may be due to its beneficial effects on Treg and restoration of immune homeostasis.     

INVESTIGATION OF REGULATORY T CELLS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Objective To evaluate the prevalence of CD4 ^＋ CD25^high regulatory T cells （ Treg cells） in the peripheral blood mononuclear cells （PBMC） and tumor-infiltrating lymphocytes （TIL） of patients with non-small cell lung cancer （NSCLC） and to investigate immunosuppression to the progression of cancer. Methods Peripheral blood and tumor tissues were collected from 20 patients with NSCLC at the time of surgery. None of the patients received surgery, radiotherapy, chemotherapy, or other medical interventions before this study. Cancer stages of the patients were Ⅰ-Ⅲ A. Venous blood samples were obtained from 20 health donors. PBMC were isolated from blood samples by differential centrifugation over Ficoll-Hypaque. TILs were isolated from tumors by differential centrifugation over Ficoll-Hypaque and Percoll. Percentage of CD4^＋ CD25^highTr/CD4＋T in PBMC and TIL was assessed by the flow cytometry. Results The percentage of CD4^ ＋ CD25high Tr/ CD4 ^＋T in PBMC [ （4. 87 ± 1.22 ） % ] of NSCLC patients was significantly higher than that in healthy donors [ （ 2.36 ± 0. 72 ） % ] （ P 〈 0.01 ）. The percentage of CD4^＋ CD25^highTr/ CD4^＋ T in PBMC [ （5.40 ± 1.20） % ] of NSCLC patients in stage Ⅱ-Ⅲ A was significantly higher than that in stage Ⅰ [ （3. 87 ± 0. 22 ） % ] （ P 〈 0. 01 ）. The percentage of CD4 ＋ CD25hiShTr/ CD4 ＋ T in TIL[ （ 8. 66 ±0. 76） % ] of NSCLC patients in stage Ⅱ-Ⅲ A was significantly higher than that in stage Ⅰ [ （ 7. 04 ± 0. 80） % ] （ P 〈 0. 01 ）. Conclusion The prevalence of CD4 ^＋ CD25^highTreg cells in PBMC and TIL of NSCLC patients was significantly higher than that in healthy donors. These Treg cells may be preventing appropriate antitumor immune responses. The population of CD4^ ＋ CD25^highTreg cells in PBMC and TILs of NSCLC patients with Ⅱ-Ⅲ A stage was significantly higher than that of NSCLC patients with Ⅰ stage. These Treg cells may facilitate development of tumors.     

Analysis of Epstein-Barr viral DNA load,EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4^＋CD25^＋ T ceils in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen

Background Epstein-Barr virus （EBV） is a herpesvirus commonly associated with several malignant diseases including nasopharyngeal carcinoma （NPC）, which is a common cancer in Southeastern Asia. Previous studies showed that plasma levels of EBV-DNA might be a sensitive and reliable biomarker for the diagnosis, staging and evaluating of therapy for NPC. There are a few analyses of the levels of EBV-latent membrane protein 2 （LMP2）-specific cytotoxic T-lymphocytes （CTLs） in patients with NPC. This study was conducted to investigate the levels of EBV-LMP2-specific CTLs, EBV-DNA load and the level of CD4^＋CD25^＋T cells in such patients.
Methods From February 2006 to April 2006, 62 patients with NPC, 40 healthy virus carriers positive for EBV viral capsid antigen （EBV-IgA-VCA） and 40 controls were enrolled in the study. We used a highly sensitive ELISPOT assay, real-time polymerase chain reaction （PCR） and flow cytometry to measure the EBV-LMP2-specific CTL response, the EBV DNA load and the level of CD4^＋CD25^＋T cells, respectively.
Results The EBV-LMP2-specific CTL responses of the samples from the control, healthy virus carriers and patients with NPC were significantly different from the LMP2 epitopes, with the control and healthy virus carrier samples displaying a stronger response in three cases. There were significant differences in EBV DNA load in serum between NPC and the healthy groups; patients with NPC at stages Ⅲ or Ⅳ had significantly higher viral loads compared with those at stages Ⅰ or Ⅱ. A significantly higher percentage of CD4^＋CD25^＋ T lymphocytes were detected in the patients, compared with healthy virus carriers and healthy controls. Moreover, patients with advanced stages of NPC （Ⅲ and Ⅳ） had significantly higher percentages than the patients with early stages （Ⅰ and Ⅱ）. Conclusions Patients with NPC are frequently unable to establish or maintain sufficient immunosurveillance to control proliferating B cells harboring EBV and to destroy the tumor cells that express immunodominant LMP2 proteins.
Controlling the activity of CD4^＋CD25^＋T cells and elevating CD8^＋ cells specific for LMP2 epitopes could be an effective immunotherapy for patients with NPC.     

Influence of Danshen Injection on airway inflammation and CD4^＋CD25^＋ regulatory T cells of asthmatic rats

Objective： To investigate the influence of Danshen Injection on airway inflammation and CD4^＋CD25^＋ regulatory T cells（CD4^＋CD25^＋ Tr） of asthmatic rats, and elucidate the possible mechanism of Danshen Injection in treatment of asthma. Methods： 30 Wister rats were randomly divided into control group, asthma group and Danshen Injection treated group. Bronchoalveolar lavage fluids （BALF） were collected, and cytology studies were conducted. Lung tissues were obtained and pathologic analyses were done with hematoxylin and eosin stain （HE）. Flow cytometry was used to detect the CD4^＋CD25^＋ Tr ratio in peripheral blood mononuclear cells （PBMCs）. Results： Total cell, the percentage of lymphocytes, neutrophils and eosinophils （Eos） in BALF of Danshen Injection-treated group were lower than that in asthma group （P〈0.05, P〈0.01）. Compared with asthma group, less infiltration of inflammatory cells in lung tissues was observed in Danshen Injection-treated group. CD4^＋CD25^＋ Tr of asthma group was lower than that of control and Danshen Injection treated group （P〈0.05）. Conclusion： Danshen Injection can suppress airway inflammation of asthmatic rats, probably by increasing the number of CD4^＋CD25^＋ Tr.     

Changes of CD4＋ CD25＋ Regulatory T Cells in Peripheral Blood in Patients with Hepatocellular Carcinoma Before and after TACE

This study investigated the changes of CD4＋ CD25＋ regulatory T cells （Tregs） in periph-eral blood of patients with hepatocellular carcinoma before and after transcatheter arterial chemoem-bolization （TACE）. The proportion of CD4＋ CD25＋ Tregs among CD4＋ T lymphocytes in peripheral blood of 33 patients with hepatocellular carcinoma was determined by flow cytometry before, 1 week and 1 month after TACE. And 25 healthy volunteers served as control. One month after TACE, the patients were divided into two groups： 22 in group A, who were in stable condition or getting better; and 10 in group B, who were deteriorating. One patient died and was excluded. The results showed that the percentage of CD4＋CD25＋ Tregs among CD4＋ T lymphocytes did not significantly change in the 33 patients 1 week after TACE as compared with that before TACE, however, the difference was significant （P〈0.01） between the patients with hepatocellular carcinoma and the healthy subjects. The percentage of CD4＋ CD25＋ Tregs among CD4＋ T lymphocytes in group A 1 month after TACE was decreased significantly in comparison with that before and 1 week after TACE （P〈0.01）, whereas, that in group B was increased significantly 1 month after TACE （P〈0.01）. It was concluded that patients with hepatocellular carcinoma had a higher proportion of CD4＋CD25＋ Tregs in peripheral blood. TACE did not significantly affect the level of CD4＋ CD25＋ Tregs within short time （such as 1 week）. The proportion of CD4＋CD25＋ Tregs in peripheral blood 1 month after TACE was related to the prognosis of hepatocellular carcinoma.     

Correlation of Thl7 cells and CD4＋CD25＋ regulatory T cells with clinical parameters in patients with systemic sclerosis

Background Systemic sclerosis （SSc） is an autoimmune disease that has three major components： inflammation, fibrosis, and vasculopathy. T-helper 17 cell （Th17） and regulatory T cell （Treg） are considered to be critical for autoimmune disease pathogenesis. The role of Th17 and Treg in SSc is still unclear. The aim of this study was to detect the presence of Th17s and CD4＊CD25~ Tregs in peripheral blood samples from SSc patients and to investigate the possible roles of these two T cell subsets in SSc pathogenesis. Methods Th17s （CD4 and IL-17 positive） and CD4＊CD25~ Tregs （CD4, CD25 and Foxp3 positive） in the peripheral blood mononuclear cells of 53 SSc patients and 27 healthy controls were counted by flow cytometry. The differences between SSc and control patients were analyzed. Clinical parameters, including disease duration, duration of the second symptoms, Modified Rodnan Skin Score （MRSS）, anti-topoisomerase I antibody, anti-U1 ribonucleoprotein （RNP） antibody, systemic involvements, pulmonary function test （PFT） and high resolution computed tomography （HRCT） score were prospectively collected following EUSTAR （EULAR scleroderma trial and research group） protocols. The correlations between the experimental and clinical data were investigated. Results The ratio of Th17 in SSc patients was significantly elevated compared to healthy controls （8.74% vs. 4.41%, P 〈0.001）. The amount of Th17 was positively correlated with disease duration （R=-0.531, P=-0.013） and duration of the second symptoms （R=-0.505, P=0.023）. The ratio of CD4＊CD25＊ Treg in SSc patients also significantly differed from the healthy controls （3.04% vs. 2.24%, P=0.018）. Elevated Tregs were more frequently observed in patients with a high interstitial lung disease （ILD） score on computed tomography （24/36） compared with patients with normal ILD scores （4/12, ,P=-0.043）. Elevated Tregs were also more often observed in patients with low carbon monoxide diffusing capacity     

系统性红斑狼疮患者外周血CD4+ CD39+ T细胞中FOXP3蛋白的表达及糖皮质激素对其影响

目的 研究系统性红斑狼疮(SLE)患者外周血CD4+ CD39+ T细胞中FOXP3蛋白的表达情况,以及糖皮质激素治疗的影响.方法 采用流式细胞术检测47例SLE患者(其中29例为初发未经治疗的活动期SLE)和22名正常人外周血CD4+ CD25+ CD39+ T细胞、CD4+CD25+ FOXP3+ T细胞及CD4+ CD39+ FOXP3+ T细胞百分率以及FOXP3蛋白的表达,分析3组细胞之间的相关性及糖皮质激素治疗的影响.结果 SLE活动组、缓解组、正常对照组外周血CD4+ CD25+ CD39+ T细胞百分率分别为(1.3±0.5)%、(1.9±0.8)%、(2.3±1.0)%,该群细胞在SLE活动组中的表达水平低于缓解组和正常对照组(均P<0.05),而在后2组之间差异无统计学意义(P>0.05);SLE活动组中CD4+ CD25+、CD4+ CD25high及CD4+ CD39+ T细胞表达的FOXP3蛋白百分率分别为(45±12)%、(65±14)%、(70±14)%,FOXP3蛋白在CD4+ CD39+ T细胞和CD4+ CD25highT细胞中的表达水平明显高于在CD4+CD25+T细胞中的表达水平(P<0.01),而在CD4+ CD39+T细胞与CD4+CD25highT细胞中的表达水平差异均无统计学意义(均P>0.05).结论 CD39可能是调节性T细胞较好的表面标记,CD39+ Treg细胞表达异常可能参与SLE的发病机制.     

CD4~+CD25~+FOXP3~+Treg细胞在高危多发性骨髓瘤治疗中预测复发及治疗意义

目的 探讨CD4+CD25+FOXP3+调节性T淋巴细胞(Treg)在高危多发性骨髓瘤治疗中预测复发及治疗意义。方法 选择2018年3月至2019年3月我院收治的126例高危多发性骨髓瘤患者为病例组,同期在我院体检健康者100例为对照组,比较病例组和对照组不同化疗疗效、不同复发情况患者外周血CD4+CD25+FOXP3+Treg细胞比例,用Spearman相关性分析CD4+CD25+FOXP3+Treg细胞比例与患者复发的相关性,用受试者工作特征曲线(ROC)分析CD4+CD25+FOXP3+Treg细胞比例预测患者复发的价值,并进行CD4+CD25+FOXP3+Treg细胞比例不同患者随访期间无进展生存的Kaplan-Meier分析。结果 病例组CD4+CD25+FOXP3+Treg细胞比例远高于对照组(P0.001);化疗无效患者CD4+CD25+FOXP3+Treg细胞比例远高于化疗有效患者(P0.001);复发患者CD4+CD25+FOXP3+Treg细胞比例远高于未复发患者(P0.001);CD4+CD25+FOXP3+Treg细胞比例与患者复发呈正相关(P0.05);CD4+CD25+FOXP3+Treg细胞比例预测患者复发的AUC(95%CI:0.759～0.856)为0.809,敏感性为62.80%,特异性为95.80%,准确性为89.30%,截断值为3.66%。CD4+CD25+FOXP3+Treg细胞比例3.66%组随访期间无进展生存率显著低于CD4+CD25+FOXP3+Treg细胞比例3.66%组(P0.05)。结论 CD4+CD25+FOXP3+Treg细胞比例在高危多发性骨髓瘤患者外周血中呈上升状态,其水平检测对于化疗后复发有一定预测价值,有助于临床预测化疗效果、监测早期复发及预后判断。     

慢性乙型肝炎患者CD4+ CD25+调节性T细胞免疫抑制功能的研究

目的 探讨慢性乙型肝炎患者CD4+ CD25+调节性T细胞(Treg)免疫抑制功能.方法 收集北京大学人民医院22例慢性乙型肝炎(CHB)患者外周血单个核细胞(PBMC)以及18名健康对照的PBMC标本,以流式分析对PBMC中CD4+ CD25+ Treg的频率进行分析;5-溴脱氧尿嘧啶核苷(BrdU)掺入法评价CD4+ CD25+ Treg的免疫抑制功能;并同时通过磁珠分选去除CHB患者PBMC中的CD4+ CD25+ Treg,分别以MHC-肽-五聚体法和酶联斑点免疫法(Elispot)检测HBVcore18-27抗原肽刺激对HBV特异性的细胞毒性T淋巴细胞(CTLs)的频率以及IFN-γ的分泌.结果 CHB患者外周血中CD4+ CD25+ Treg细胞群所占CD4+T细胞群的比例明显高于健康对照(t=3.74,P＜0.01);CHB患者CD4+ CD25+ Treg细胞可非特异抑制自身活化的CD4+ CD25- T细胞,并呈剂量依赖的特点,且抑制能力与健康对照相比无明显差异;在经HBVcore18-27抗原肽诱导条件下,去除CD4+ CD25+ Treg CHB患者,HBVcore18-27特异性CTLs的频率以及CTLs分泌IFN-γ的频数与未去除CD4+ CD25+ Treg组比出现显著上调(t=4.75,t=7.828,P＜0.01).结论 CHB患者循环中CD4+ CD25+ Treg细胞频率升高.在体外去除CHB患者PBMC的CD4+ CD25+ Treg后可显著地增强HBV抗原诱导的抗HBV细胞免疫应答.     

胃癌患者外周血CD4+ CD25high调节性T细胞比率及表型特征研究

目的：探讨胃癌患者外周血高表达CD25的CD4＋调节性T细胞（CD4＋CD25highT）比率变化特点及其临床意义。方法：用流式细胞术检测50例肿瘤患者和20名健康人外周血CD4＋CD25highT细胞水平,初步探讨其表型特征。并分析10例胃癌患者手术后1周外周血调节性T细胞与手术前相比的变化。结果：胃癌患者外周血中CD4＋CD25highT细胞占CD4＋T细胞的百分比率为（14.67±6.55）%,明显高于健康体检者（3.41±1.13）%（P〈0.01）;CD4＋CD25highT细胞具有调节性T细胞的表面标记特征,高水平表达FOXP3、CD152（CTLA-4）、CD134（OX40）和GITR。胃癌各期CD4＋CD25highT细胞占CD4＋T细胞的比率均显著高于正常对照组（P〈0.01）。胃癌患者术后外周血CD4＋CD25highT细胞比率与术前相比明显降低（P〈0.05）。结论：胃癌患者外周血CD4＋CD25highT细胞水平明显升高,可能与肿瘤免疫功能低下及肿瘤发生发展密切相关。     

人 CD4+T细胞在肠道细菌抗原刺激前后CD25与FOXP3的表达

目的：探讨新鲜分离及自身肠道菌群抗原刺激后的人外周血CD4^＋T细胞CD25和FOXP3表达的相关性及变化规律．方法：分离人的外周血单核细胞和淋巴细胞，单核细胞经自身肠道菌群抗原刺激后与淋巴细胞混合培养，新鲜分离及混合培养14d的淋巴细胞用三色流式细胞术在单细胞水平同时检测CD4，CD25和FOXP3的表达．结果：新鲜分离的淋巴细胞约43．4％表达CD4，在CD4^＋T细胞中，约5．8％表达CD25，而高表达的只有1．9％，约5．2％表达FOXP3，CD25和FOXP3均表达的占3．3％，CD25^hi FOXP3^＋细胞占1．6％，CD4^-细胞几乎不表达FOXP3．经抗原刺激后，淋巴细胞总数均轻度增加（与未刺激组比较，平均增加21．0％，P〈0．001）．CD4^＋细胞的比例均明显上升（67．1％vs43．4％，P〈0．001），CD25^＋，FOXP3^＋及CD25^＋FOXP3^＋细胞的比例变化不大．CD4^＋CD25^＋FOXP3^＋T细胞占CD4^＋CD25^＋T细胞的比例及CD4^＋CD25^hi FOXP3^＋T细胞占CD4^＋CD25^hiT细胞的比例在所有研究对象中均呈下降趋势（前者从59．8％降到52．0％，后者从86．3％降到77．9％，均P〈0．05）．结论：CD25和FOXP3的表达具有一定的相关性，但CD25及CD25^hi均不能很可靠地标记人类的调节性T细胞，尤其是在淋巴细胞受到抗原刺激以后．肠道菌群抗原作为外来抗原刺激自身的淋巴细胞后，活化增殖的细胞中主要是CD4^＋CD25^＋FOXP3^-反应性T细胞，而不是CD4^＋CD25^＋FOXP3^＋调节性T细胞．     

CD4+CD25+调节性T细胞对直肠癌过继免疫治疗效应细胞的影响和作用

目的 探讨CD4+CD25+调节性T细胞（Treg）在直肠癌过继免疫治疗中对免疫杀伤细胞的负性调节作用。方法 利用流式细胞仪分别检测15例直肠癌患者和健康志愿者外周血中CD4+CD25+调节性T细胞的含量；分离提取直肠癌患者外周血CD4+T细胞，免疫磁珠法去除 CD4+CD25+调节性T细胞，同灭活的LOVO直肠癌细胞珠共培养并扩增为肿瘤抗原特异性CTL，以LOVO细胞为靶细胞行肿瘤杀伤实验，观察各实验组CTL对肿瘤细胞的杀伤效应。结果 直肠癌患者外周血中CD4+CD25+调节性T细胞占CD4+T细胞总数的（11.12±0.57）%，显著高于健康对照组（8.77±0.66）%（t=2.687，P＝0.012）；去除Treg细胞后诱导产生的抗原特异性CTL对靶细胞的杀伤效率为（33.74±4.42）%，显著高于未去除Treg细胞的对照组CTL的杀伤效率[(17.39±2.54)%; t=3.206, P=0.0034]。结论　直肠癌患者外周血中调节性T细胞含量明显增高，并且对肿瘤抗原诱导的CTL的免疫杀伤功能具有明显抑制作用。     

CD4+ CD25+ CD127low/-T细胞在系统性红斑狼疮活动期患者中的表达

目的 检测调节性T细胞(Treg)的新旧标志,进一步探讨Treg细胞在系统性红斑狼疮(SLE)发病中的作用.方法 采用三色直接荧光素标记法和多参数流式细胞术检测29例SLE患者及24例正常对照组外周血CD4+ CD25+ CD127low/-T细胞、CD4+ CD25highT细胞及CD4+ CD25+FOXP3+T细胞的比例,同时检测外周血抗dsDNA等抗体及免疫球蛋白、补体等水平并进行相关分析.结果 SLE患者外周血CD4+ CD25+ CD127low/-T细胞与正常对照组差异无统计学意义(P＞0.05),CD4+ CD25+ FOXP3+T细胞[(2.1±1.2)%]及CD4+ CD25highT细胞[(0.8 ±0.4)%]与正常对照组[(1.8±0.8)%及(4.0±1.4)%]比较差异有统计学意义(P＜0.01);SLE组3种细胞占CD4+ CD25+T细胞的比例均明显低于正常对照组(均P＜0.01),CD4+ CD25+ CD127low/-T细胞、CD4+CD25+ FOXP3+T细胞及CD4+ CD25highT细胞分别占CD4+ CD25+T细胞的比例及与年龄、性别和病程,IgG、IgA、IgM、尿蛋白,24 h蛋白尿,抗dsDNA、抗Clq、抗核小体抗体水平均无相关性(均P＞0.05);但其与SLEDAI评分均存在负相关(P＜0.05).仅CD+ CD25+ GD127low/-T细胞/CD+ CD25+T细胞与补体C4存在明显的负相关(P＜0.01).结论 Treg细胞与活化的CD4+T细胞的相对比例可能在SLE的发病中起到重要作用.     

FOLFOX方案化疗对胃癌术后患者外周血CD4+CD25+调节性T细胞细胞增殖及功能的影响

目的探讨FOLFOX方案化疗对胃癌术后患者外周血CD4+CD25+调节性T细胞(Treg细胞)比例及功能的影响。方法选择43例胃癌术后化疗患者,于化疗前1天、化疗结束后第5天采集外周血。采用流式细胞法检测外周血Treg细胞的比例;RT-PCR法检测外周血Treg细胞FoxP-3 mRNA表达水平;将分选的Treg细胞和CD4+CD25-T细胞按单纯Treg细胞组、1∶1混合细胞组,单纯CD4+CD25-T细胞组培养,3H-TdR掺入法检测Treg细胞体外抑制CD4+CD25-T细胞增殖的能力。结果 43例胃癌患者化疗前1天外周血Treg细胞占CD4+T细胞的比例为17.63%±6.31%,化疗后降至13.79%±4.82%(P<0.01);化疗后FoxP-3表达水平较化疗前显著下降(P<0.01);化疗后Treg细胞对CD4+CD25-T细胞的增殖抑制率由化疗前的54.64%±5.15%下降至24.63%±2.34%(P<0.01)。结论 FOLFOX化疗方案可减少胃癌患者外周血Treg细胞数量,下调其表面标志物FoxP3基因的表达水平,减弱Treg细胞的免疫抑制功能,有利于诱生抗肿瘤免疫效应。     

胃癌手术前后外周血CD4^＋CD25^＋调节性T细胞的变化及临床意义

目的：检测CD4^＋CD25^＋调节性T细胞（Treg）在胃癌手术前后外周血中的变化,探讨Treg在肿瘤免疫中的作用。方法：收集初治胃癌患者38例作为研究对象,同时收集20例健康人外周血作为正常对照组。检测手术前3d和手术后14d外周血中CD4^＋CD25^＋Treg比例及T细胞亚群,将各检测结果结合临床、病理指标进行统计学分析。结果：胃癌患者术前外周血中Treg比例显著高于术后比例以及对照组（P均〈0．01）。胃癌患者术前外周血CD8^＋T细胞比例明显低于术后比例以及对照组（P均〈0．01）。术前外周血CD8^＋T细胞比例与Treg比例呈负相关（P〈0．05）。胃癌患者术前外周血中Treg比例在不同淋巴结转移情况和TNM分期之间差异具有统计学意义（P〈0．05）,其与淋巴结转移和TNM分期呈正相关（P〈0．01）。胃癌患者手术后Treg比例较术前下降,且下降程度与浸润深度、淋巴结转移、远处转移、TNM分期、分化程度、病理分型以及手术方式无相关性。结论：Treg可能通过抑制CD8^＋T细胞的增殖及功能,促进肿瘤细胞的生长和发展。Treg与肿瘤的侵袭、淋巴结转移有关,提示Treg在一定程度上可作为检测疾病进展的免疫学指标。     

非小细胞肺癌外周血CD4^＋CD25^＋FoxP3^＋调节T细胞分析

目的分析非小细胞肺癌（NSCLC）患者外周血CD4^＋CD25^＋FoxP3^＋调节T细胞（Treg）占CD4^＋T细胞的比例变化,探讨其临床意义。方法采用流式细胞仪检测32例非小细胞肺癌患者和15例正常健康者（对照组）外周血中CD4^＋CD25^＋FoxP3^＋Treg占CD4^＋T细胞的比例。结果健康对照纽外周血CD4^＋CD25^＋FoxP3^＋Treg占CD4^＋T细胞比例为（0．54±0．51）％;NSCLC患者外周血CD4^＋CD25^＋FoxP3^＋Treg占CD4^＋T细胞比例为（1．40±0．98）％。两组比较差异有统计学意义（P〈0．01）。结论NSCLC患者外周血CD4^＋CD25^＋FoxP3^＋Treg占CD4^＋T细胞的比例明显升高,提示与肺癌免l癌逃逸有美。